The anticancer activity of the drug candidates was tested in two NSCLC cell lines harboring EGFR sensitizing mutation (HCC827: E746_A750 deletion) or resistance-causing EGFR secondary mutation (H1975: L858R/T790M). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.